By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

A novel cooled laser focal therapy device demonstrates 84% treatment success for localized prostate cancer at 3 months, with only 12% reporting erectile dysfunction and minimal impact on urinary ...

Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...

A novel theranostic approach that targets RET—a newly identified biomarker for neuroendocrine prostate cancer—enables ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical textbooks present as relatively binary: remove the entire prostate gland or ...

The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through ...

About 1 in 8 men will learn they have prostate cancer at some point in their lifetime. And while most of those who are diagnosed will survive, prostate cancer can be serious. It's the second-leading ...